Pharmacokinetics of the Digoxin-Quinidine Interaction via Mixed-Effect Modelling
暂无分享,去创建一个
M. A. Mergener | Paul J. Williams | James Lane | William Murray | Michael A. Mergener | Masanobu Kamigaki | Paul J. Williams | W. Murray | J. Lane | M. Kamigaki
[1] T. Beveridge,et al. Absolute bioavailability of digoxin tablets. , 1978, Arzneimittel-Forschung.
[2] D. Greenblatt,et al. Single‐ and multiple‐dose kinetics of intravenous digoxin , 1980, Clinical pharmacology and therapeutics.
[3] W. Oetgen,et al. Amiodarone-digoxin interaction. Clinical and experimental observations. , 1984, Chest.
[4] H. Halkin,et al. Determinants of the renal clearance of digoxin , 1975, Clinical pharmacology and therapeutics.
[5] W. Jusko,et al. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses , 1975, Journal of Pharmacokinetics and Biopharmaceutics.
[6] T. Smith. Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. , 1975, The American journal of medicine.
[7] J. Doherty,et al. The distribution and concentration of tritiated digoxin in human tissues. , 1967, Annals of internal medicine.
[8] E. Haber,et al. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. , 1970, The Journal of clinical investigation.
[9] J. Bigger,et al. Interaction between quinidine and digoxin. , 1978, JAMA.
[10] W. Jusko,et al. Pharmacokinetic Design of Digoxin Dosage Regimens in Relation to Renal Function , 1974, Journal of clinical pharmacology.
[11] D. D. Bois,et al. CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .
[12] P. Welling,et al. Calculation of Serum Digoxin Levels in Patients with Normal and Impaired Renal Function , 1976, Journal of clinical pharmacology.
[13] W. Jusko,et al. Digoxin pharmacokinetics: Role of renal failure in dosage regimen design , 1975, Clinical pharmacology and therapeutics.
[14] J. D. Andersen,et al. Spironolactone‐induced changes in digoxin kinetics , 1978, Clinical pharmacology and therapeutics.
[15] M. Mellow,et al. Variation in biologic availability of digoxin from four preparations. , 1971, The New England journal of medicine.
[16] P. Ongley,et al. The distribution and excretion of tritiated substances in experimental animals following the administration of digoxin-3H. , 1966, The Journal of laboratory and clinical medicine.
[17] J. Aronson. Clinical Pharmacokinetics of Cardiac Glycosides in Patients with Renal Dysfunction , 1983, Clinical pharmacokinetics.
[18] W. Doering. Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications. , 1979, The New England journal of medicine.
[19] E. Besenfelder,et al. Quinidine-digoxin interaction: Evidence for involvement of an extrarenal mechanism , 2004, European Journal of Clinical Pharmacology.
[20] P. Pentikäinen,et al. Association between clinical cardiac status, laboratory parameters, and digoxin usage. , 1976, American heart journal.
[21] D. Mungall,et al. Effects of quinidine on serum digoxin concentration: a prospective study. , 1980, Annals of internal medicine.
[22] D. DuBois,et al. A formula to estimate the approximate surface area if height and weight be known , 1989 .
[23] F. Nielsen‐Kudsk,et al. Digoxin‐verapamil interaction , 1981, Clinical pharmacology and therapeutics.
[24] K. Schenck-Gustafsson,et al. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. , 1981, British journal of clinical pharmacology.
[25] J. Bigger,et al. The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. A prospective study. , 1980, Annals of internal medicine.
[26] A. Hastreiter,et al. Postmortem Tissue Digoxin Concentrations in Infants and Children , 1975, Circulation.